Trials / Active Not Recruiting
Active Not RecruitingNCT05990452
Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors
A Phase I/II First-in-human Study of 9MW2921 to Evaluate the Safety, Tolerability and Preliminary Efficacy of 9MW2921 in Patients With Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 261 (estimated)
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, Phase I-II, first-in-human (FIH) study of 9MW2921 in patients with locally advanced or metastatic solid tumors refractory to all standard therapies. The objective of this study is to evaluate the safety, tolerability, PK, immunogenicity and Preliminary Antitumor Activity of 9MW2921.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 9MW2921 | All subjects will receive 9MW2921 by intravenous (IV) every 3 weeks. |
Timeline
- Start date
- 2023-08-28
- Primary completion
- 2026-09-01
- Completion
- 2026-12-30
- First posted
- 2023-08-14
- Last updated
- 2024-11-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05990452. Inclusion in this directory is not an endorsement.